Bruno António Cardoso has a total of 112 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Epigenetic alterations in Myeloid Malignancies

    by Bruno António Cardoso

    Epigenetic alterations have emerged as central contributors to the pathogenesis, progression, and therapeutic response in cancer, and in this particular case, which we are discussing, myeloid malignancies. Unlike genetic mutations, epigenetic changes, like DNA methylation and histone modifications, are reversible and dynamic, and this book chapter aims to provide a comprehensive overview of the fundamental principles of epigenetic regulation and explores how these mechanisms are disrupted across different myeloid malignancies. We will examine disease-specific epigenetic landscapes and highlight the key alterations that occur within myeloid malignancies and discuss how such alterations can contribute to leukemogenesis and disease progression. Altogether, this chapter emphasizes the central role of epigenetic dysregulation in shaping the biology and clinical behavior of myeloid malignancies.

  • Epigenetic Targeting in Myeloid Malignancies

    by Bruno António Cardoso

    Epigenetic deregulation is a hallmark of myeloid malignancies, shaping their initiation, progression, and therapeutic response. Unlike genetic alterations, epigenetic modifications, such as DNA methylation, histone acetylation, and chromatin remodeling, are reversible, making them attractive targets for pharmacological intervention. This chapter aims to provide a detailed and comprehensive overview of epigenetic drugs currently available in both preclinical and clinical testing, with a particular focus on agents directed against histone deacetylases (HDACs), DNA methyltransferases (DNMTs), histone methyltransferases (HMTs), histone demethylases (HDMs), bromodomain and extra-terminal (BET) proteins, and mutant IDH1/2 enzymes. By detailing the mechanisms of action and the available translational data for these pharmacological agents, the chapter aims to summarize the current state of epigenetic therapy and highlight how the development of epigenetic therapies is shaping the clinical landscape of myeloid malignancies.

  • Open Access

    Editorial: Two decades of targeted therapies in hematology: new targets and novel combinations

    by Bruno António Cardoso, Natalia Neparidze

    Expanded this initial objective into other crucial areas covering disease biology and precursor conditions.Taborda et al wrote a review manuscript describing the importance of discriminating CCUS as an independent hematological entity from Clonal hematopoiesis of Indetermined Potential (CHIP) (1). As the authors discuss in the article, CHIP is defined as a condition characterized by the acquisition of somatic mutations commonly found in myeloid malignancies with a variant allele fraction (VAF) of ≥2% in the absence of hematologic malignancy or unexplained cytopenia when such cytopenia is persistent is it classified as CCUS. The incidence of CCUS is around 30% in patients who do not meet the criteria for Myelodisplastic syndromes (MDS) (2). The CCUS mutational landscape overlaps CHIP and MDS and includes genes commonly mutated in myeloid neoplasms (TET2, DNMT3A, ASXL1, and others). Increased understanding of clonality (through genome-wide association studies) led to the development of risk stratification tools to assess the likelihood of progression to myeloid neoplasms.Finally, the authors also discuss potential therapeutic targets that are currently being tested in the context of CCUS; these include epigenetic regulators (TET2 and IDH1/2) and deregulated inflammation signaling.Hematopoiesis is the complex process that gives rise to all the blood cellular lineages cells (3). This complex process occurs in a particular microenvironment and, when disrupted, allows for leukemic transformation and proliferation. The bone marrow comprises different cellular components that modulate and regulate hematopoiesis, and understanding these interactions is essential for developing effective therapies. In the review by Semedo and Caroço, the authors suggest that successful treatment of leukemia may require strategies that simultaneously target leukemic cells and the supportive microenvironmentthe dual targeting approach. This targeting approach could improve patient outcomes and reduce the likelihood of resistance to therapies. To illustrate their claims, the authors provide a comprehensive and detailed overview of all the clinical studies using therapeutic strategies targeting leukemic cells and the bone marrow microenvironment.Wei and Konopleva provided a comprehensive overview of the role of Bcl-2 inhibitors in hematologic malignancies, highlighting their potential, challenges, and the need for personalized treatment approaches in blood cancers. The Bcl-2 protein is a crucial regulator of apoptosis and is often upregulated in blood cancers, which makes them an attractive target in cancer research (4)(5).Venetoclax is the first FDA-approved Bcl-2 inhibitor to treat malignancies where this antiapoptotic protein is aberrantly overexpressed (6). The authors discuss the clinical applications of Venetoclax in several conditions, particularly in Chronic Lymphocytic Leukemia (CLL) and Acute Myeloid Leukemia (AML), and cast the outcomes of clinical trials that demonstrate its efficacy and safety profile. Furthermore, the article also discusses the future directions in developing Bcl-2 inhibitors and combination therapies, resistance mechanisms, and the need for personalized treatment approaches.Phillips et al conducted a retrospective review of 31 B-cell Acute Lymphoblastic Leukemia (B-ALL) patients who received Anti-CD19 CAR-T cell therapy (Tisagenlecleucel) (7)(8). The authors analyzed clinical data (response, survival rates, and remission duration) from relapsed or refractory B-ALL patients treated with Anti-CD19 CAR-T cell therapy without prior hematopoietic stem cell transplantation (HSCT). Notably, the results suggest that in a significant proportion (12/31) of relapsed/refractory B-ALL patients, Anti-CD19 CAR-T cell therapy is sufficient to induce long-term remissions without the need for further therapy but also to delay the HSCT procedure in this difficultto-treat group of patients. The authors discuss the importance of careful assessment and clinical judgment to determine the best clinical protocol for each patient since not all patients will benefit from a high-risk procedure like HSCT.Abdallah and colleagues presented the results of the CheckMate 039 clinical trial. This is a multicentric (seven centers involved), randomized phase I/II clinical trial that tested the combination of Nivolumab (Checkpoint inhibitor) and Daratumumab (Anti-CD38) in patients with relapsed/refractory Multiple Myeloma (RRMM). The MM outcomes have improved over the years with the introduction of immunomodulatory agents, proteasome inhibitors (PIs), and monoclonal antibodies (mAbs) (9). This study evaluated Nivolumab-Daratumumab combination MM patients' safety, tolerability, and efficacy.Despite the small patient sample, this combination was safe and demonstrated encouraging efficacy signals, particularly in achieving high response rates. The findings are notable and challenge the hematology community to re-examine and re-consider the significance of a PD-1 checkpoint pathway in myeloma. These encouraging results suggest that combining immune checkpoint inhibitors with monoclonal antibodies may represent a promising strategy to improve outcomes for patients with RRMM, addressing a critical need in this patient population where a clinical unmet need still exists.In conclusion, even though the articles that compose this research topic extend beyond the intended original scope, they provide not only original data on therapeutic targeting of hematological malignancies but also essential reflections on the targets and strategies that the scientific research community should take into consideration to develop effective therapies for such patients. Notably, the introduction of cutting-edge diagnostic tools like next-generation sequencing and single-cell sequencing, a conscious effort should be put in place to provide personalized and effective treatment for patients with hematological malignancies.BAC:...

  • Open Access

    Targeting the bone marrow niche, moving towards leukemia eradication

    by Carla Semedo, Raquel Caroço, António Almeida, Bruno António Cardoso, Ant

    Hematopoiesis is a complex and tightly regulated process that drives the formation of mature blood cells from a single hematopoietic stem cell. This complex process occurs within the bone marrow, which, once disrupted or deregulated, subverts normal hematopoietic development, allowing leukemic cells to emerge, proliferate, and thrive. Notably, several cellular populations and paracrine factors within the bone marrow fuel leukemia expansion and progression. This review presents an overview of the main microenvironmental components that promote myeloid leukemia progression, discussing the emerging therapeutical strategies that target both leukemic cells and the supportive bone marrow microenvironment – targeting both the seed and the soil.


  • The Bone Marrow Niche – The Tumor Microenvironment That Ensures Leukemia Progression

    by Bruno António Cardoso

    The human body requires a constant delivery of fresh blood cells that are needed to maintain body homeostasis. Hematopoiesis is the process that drives the formation of new blood cells from a single stem cell. This is a complex, orchestrated and tightly regulated process that occurs within the bone marrow. When such process is faulty or deregulated, leukemia arises, develops and thrives by subverting normal hematopoiesis and availing the supplies of this rich milieu. In this book chapter we will describe and characterize the bone marrow microenvironment and its key importance for leukemia expansion. The several components of the bone marrow niche, their interaction with the leukemic cells and the cellular pathways activated within the malignant cells will be emphasized. Finally, novel therapeutic strategies to target this sibling interaction will also be discussed.


  • Vorinostat synergizes with antioxidant therapy to target myeloproliferative neoplasms

    by Bruno A. Cardoso, Teresa L. Ramos, Hélio Belo, Filipe Vilas-Boas, Carla Real, António M. Almeida


  • Acetylation drives hepatocyte nuclear factor 1β stability by blocking proteasome‐mediated degradation

    by Filipa Lopes‐Coelho, Fernanda Silva, Ana Hipólito, Bruno A. Cardoso, Jacinta Serpa

    Hepatocyte nuclear factor 1β (HNF1β) is mostly expressed in the liver, but is also expressed in other organs, like kidney, pancreas and genitourinary tract. In fact, HNF1β, a member of the superfamily of homeodomain‐containing transcription factors, has been described as a hallmark in clear cell carcinomas. However, its role as an oncogene or as tumor suppressor gene remains controversial. Here, we disclose a mechanism of HNF1β stabilization and degradation, using human HNF1β‐expressing cell lines of ovarian clear cell carcinoma (ES2), hepatocellular carcinoma (HEPG2), and normal immortalized kidney tubular cells (HK2). We show that increased levels of HNF1β is concomitant with an increase in the acetylation load and protein stabilization by interfering with the ubiquitin‐proteasome degradation system. This study reinforces that acetylation, besides their role in regulating chromatin conformation and gene expression, could also act in the action, turnover and stability of proteins essential for the survival and progression of certain cancer types.


  • STAT5 is essential for IL-7–mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells

    by Daniel Ribeiro, Alice Melão, Ruben van Boxtel, Cristina I. Santos, Ana Silva, Milene C. Silva, Bruno A. Cardoso, Paul J. Coffer, João T. Barata

    T-cell acute lymphoblastic leukemia (T-ALL) constitutes an aggressive subset of ALL, the most frequent childhood malignancy. Whereas interleukin-7 (IL-7) is essential for normal T-cell development, it can also accelerate T-ALL development in vivo and leukemia cell survival and proliferation by activating phosphatidylinositol 3-kinase/protein kinase B/mechanistic target of rapamycin signaling. Here, we investigated whether STAT5 could also mediate IL-7 T-ALL-promoting effects. We show that IL-7 induces STAT pathway activation in T-ALL cells and that STAT5 inactivation prevents IL-7–mediated T-ALL cell viability, growth, and proliferation. At the molecular level, STAT5 is required for IL-7-induced downregulation of p27kip1 and upregulation of the transferrin receptor, CD71. Surprisingly, STAT5 inhibition does not significantly affect IL-7–mediated Bcl-2 upregulation, suggesting that, contrary to normal T-cells, STAT5 promotes leukemia cell survival through a Bcl-2-independent mechanism. STAT5 chromatin immunoprecipitation sequencing and RNA sequencing reveal a diverse IL-7-driven STAT5-dependent transcriptional program in T-ALL cells, which includes BCL6 inactivation by alternative transcription and upregulation of the oncogenic serine/threonine kinase PIM1. Pharmacological inhibition of PIM1 abrogates IL-7–mediated proliferation on T-ALL cells, indicating that strategies involving the use of PIM kinase small-molecule inhibitors may have therapeutic potential against a majority of leukemias that rely on IL-7 receptor (IL-7R) signaling. Overall, our results demonstrate that STAT5, in part by upregulating PIM1 activity, plays a major role in mediating the leukemia-promoting effects of IL-7/IL-7R. Key Points STAT5 is required for IL-7–mediated proliferation and viability, but it does not regulate Bcl-2 downstream from IL-7 in T-ALL cells. PIM1 is required for IL-7-induced leukemia cell cycle progression and proliferation and may be a therapeutic target for IL-7-reliant T-ALLs. Visual Abstract


  • Open Access

    From the outside, from within: Biological and therapeutic relevance of signal transduction in T-cell acute lymphoblastic leukemia

    by Mariana L. Oliveira, Padma Akkapeddi, Isabel Alcobia, Afonso R. Almeida, Bruno A. Cardoso, Rita Fragoso, Teresa L. Serafim, João T. Barata


  • Open Access

    RAC1b overexpression stimulates proliferation and NF-kB-mediated anti-apoptotic signaling in thyroid cancer cells

    by Márcia Faria, Paulo Matos, Teresa Pereira, Rafael Cabrera, Bruno A Cardoso, Maria João Bugalho, Ana Luísa Silva

    Overexpression of tumor-associated RAC1b has been recently highlighted as one of the most promising targets for therapeutic intervention in colon, breast, lung and pancreatic cancer. RAC1b is a hyperactive variant of the small GTPase RAC1 and has been recently shown to be overexpressed in a subset of papillary thyroid carcinomas associated with unfavorable outcome. Using the K1 PTC derived cell line as an in vitro model, we observed that both RAC1 and RAC1b were able to induce a significant increase on NF-kB and cyclin D1 reporter activity. A clear p65 nuclear localization was found in cells transfected with RAC1b-WT, confirming NF-kB canonical pathway activation. Consistently, we observed a RAC1b-mediated decrease in IκBα (NF-kB inhibitor) protein levels. Moreover, we show that RAC1b overexpression stimulates G1/S progression and protects thyroid cells against induced apoptosis, the latter through a process involving the NF-kB pathway. Present data support previous findings suggesting an important role for RAC1b in the development of follicular cell-derived thyroid malignancies and point out NF-kB activation as one of the molecular mechanisms associated with the pro-tumorigenic advantage of RAC1b overexpression in thyroid carcinomas.